Skip to content
10-Q

Quarterly Report

SIGYN THERAPEUTICS, INC. SIGY

0001641172-25-011815

← back to feed
Filed
May 20, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 20, 2025 1.61M sh
Shares Diluted Q1 2025 · Mar 31, 2025 1.61M sh
Shares Diluted Q1 2025 · Mar 31, 2024 1.23M sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$294.45K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$235.61K
Long Term Debt Q1 2025 · Mar 31, 2025 $2.4M
Short Term Debt Q1 2025 · Mar 31, 2025 $212.92K
Short Term Debt Q1 2025 · Dec 31, 2024 $174.21K
Cash And Equivalents Q1 2025 · Mar 31, 2025 $12.9K
Cash And Equivalents Q1 2025 · Dec 31, 2024 $12.14K
Stockholders Equity Q1 2025 · Mar 31, 2025 −$4.95M
Stockholders Equity Q1 2025 · Dec 31, 2024 −$4.46M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$4.02M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$3.41M
Current Liabilities Q1 2025 · Mar 31, 2025 $5.15M
Current Liabilities Q1 2025 · Dec 31, 2024 $4.61M
Total Liabilities Q1 2025 · Mar 31, 2025 $5.19M
Total Liabilities Q1 2025 · Dec 31, 2024 $4.67M
Current Assets Q1 2025 · Mar 31, 2025 $68.1K
Current Assets Q1 2025 · Dec 31, 2024 $21.24K
Total Assets Q1 2025 · Mar 31, 2025 $244.31K
Total Assets Q1 2025 · Dec 31, 2024 $213.72K
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.42
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.62
Eps Basic Q1 2025 · Mar 31, 2025 −$0.42
Eps Basic Q1 2025 · Mar 31, 2024 −$0.62
Sga Expense Q1 2025 · Mar 31, 2025 $487.04K
Sga Expense Q1 2025 · Mar 31, 2024 $359.54K
Rd Expense Q1 2025 · Mar 31, 2025 $8.84K
Rd Expense Q1 2025 · Mar 31, 2024 $232.59K
Net Income Q1 2025 · Mar 31, 2025 −$668.56K
Net Income Q1 2025 · Mar 31, 2024 −$758.09K
Operating Income Q1 2025 · Mar 31, 2025 −$546.06K
Operating Income Q1 2025 · Mar 31, 2024 −$629.97K